Efficacy of levetiracetam in pharmacoresistant continuous spikes and waves during slow sleep

Capovilla, Giuseppe; Beccaria, Franca; Cagdas, S.; Montagnini, Alessandra; Segala, R.; Paganelli, D.

doi:10.1111/j.1600-0404.2004.00289.x

Cited by 43 publications

(40 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two other patients without improvement of the EEG had neuropsychological improvement (Aeby et al 2005). Benefit was also reported in another small series (Capovilla et al 2004). There was 1 case report of improvement in a child with the related Laudau-Kleffner syndrome (Kossoff et al 2003).…”

Section: Levetiracetamsupporting

confidence: 57%

Levetiracetam in the treatment of epilepsy

Abou‐Khalil

2008

NDT

203

136

View full text Add to dashboard Cite

Epilepsy is a common chronic disorder that requires long-term antiepileptic drug therapy. Approximately one half of patients fail the initial antiepileptic drug and about 35% are refractory to medical therapy, highlighting the continued need for more effective and better tolerated drugs. Levetiracetam is an antiepileptic drug marketed since 2000. Its novel mechanism of action is modulation of synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A in the brain. Its pharmacokinetic advantages include rapid and almost complete absorption, minimal insignifi cant binding to plasma protein, absence of enzyme induction, absence of interactions with other drugs, and partial metabolism outside the liver. The availability of an intravenous preparation is yet another advantage. It has been demonstrated effective as adjunctive therapy for refractory partial-onset seizures, primary generalized tonic-clonic seizures, and myoclonic seizures of juvenile myoclonic epilepsy. In addition, it was found equivalent to controlled release carbamazepine as fi rst-line therapy for partial-onset seizures, both in effi cacy and tolerability. Its main adverse effects in randomized adjunctive trials in adults have been somnolence, asthenia, infection, and dizziness. In children, the behavioral adverse effects of hostility and nervousness were also noted. Levetiracetam is an important addition to the treatment of epilepsy.

show abstract

Section: Levetiracetamsupporting

confidence: 57%

Levetiracetam in the treatment of epilepsy

Abou‐Khalil

2008

NDT

203

136

View full text Add to dashboard Cite

show abstract

“…Recently, reports have suggested that LEV may be useful in CSWS. [1011] Capovilla et al . [10] reported total seizure control in two of three patients with CSWS.…”

Section: Discussionmentioning

confidence: 99%

“…[1011] Capovilla et al . [10] reported total seizure control in two of three patients with CSWS. Lennox-Gastaut syndrome is an epileptic encephalopathy characterized by multiple seizure types, mental retardation, and a slow spike-and-wave pattern on electroencephalography.…”

Section: Discussionmentioning

confidence: 99%

The efficacy and side effects of levetiracetam on refractory epilepsy in children

2012

View full text Add to dashboard Cite

Objective:To evaluate the efficacy and tolerability of levetiracetam (LEV) add-on therapy in children with refractory epilepsy.Materials and Methods:We evaluated 102 children (56 boys, 46 girls, mean age 96.00 ± 31.15 months) with refractory epilepsy. Patients received LEV as add-on therapy. Changes in seizure frequency and adverse events were observed. Follow-up was conducted at least 6 months after treatment.Results:In total, 46 (45.1%) of the 102 children achieved more than 50% seizure frequency reduction, and 16 (15.6%) of these were seizure free. LEV reduced seizure frequency by at least 50% in 58.3% of patients with partial seizures, in 32.0% of patients with primary generalized seizures, and in 17.6% of patients with both partial and generalized seizures.Conclusion:Our results confirm that LEV, as add-on therapy, was effective in reducing seizure frequency in a variety of seizure types but seems most effective for partial-onset seizures. LEV was also well-tolerated in children.

show abstract

“…Resolution of ESES had been achieved with conventional antiepileptic drugs (AEDs) including ethosuximide [28,29], valproic acid [25,30], benzodiazepines [22,[30][31][32], levetiracetam [17,33,34], and sulthiame [17,22]. When these agents fail to normalize the EEG, a trial with second-line agents such as steroids [17,[25][26][27] or high-dose diazepam [35,36] is attempted.…”

Section: Contents Lists Available At Sciencedirectmentioning

confidence: 99%

Benign childhood epilepsy with Centro-Temporal spikes (BCECTSs), electrical status epilepticus in sleep (ESES), and academic decline — How aggressive should we be?

Uliel‐Sibony

Kramer

2015

Epilepsy & Behavior

View full text Add to dashboard Cite

Efficacy of levetiracetam in pharmacoresistant continuous spikes and waves during slow sleep

Abstract: Even if our report is anecdotal, LEV expands the spectrum of antiepileptic drugs that can be used for the treatment of CSWS. LEV efficacy should be confirmed in larger series.

Cited by 43 publications

References 14 publications

Levetiracetam in the treatment of epilepsy

Levetiracetam in the treatment of epilepsy

The efficacy and side effects of levetiracetam on refractory epilepsy in children

Benign childhood epilepsy with Centro-Temporal spikes (BCECTSs), electrical status epilepticus in sleep (ESES), and academic decline — How aggressive should we be?

Contact Info

Product

Resources

About